Alcestobart

DB28487InvestigationalProtein Based Therapies

Alcestobart is a biologic drug. Alcestobart is under investigation in clinical trial NCT05909904 (A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell...

Mechanism: Pharmacologically active on Lymphocyte activation gene 3 protein
Curator reviewed
Code names: LBL-007

Resolves to

Compound

UNIIU1GA9GN97DCAS2888563-73-1

Targets

P18627LAG3

What you can answer from here — as of June 16, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Alcestobart, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account